Introduction
============

Hepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third leading cause of cancer-related deaths worldwide [@B01]-[@B03]. The estimated incidence of new HCC cases is approximately 500,000--1,000,000, causing 600,000 deaths globally each year [@B01]. HCC shows significantly geographic variation, with a very high incidence in China corresponding to approximately 55% of annual new cases of HCC worldwide [@B01],[@B04]. HCC has been one of the most common causes of cancer-related deaths in China since the 1990s [@B05],[@B06]. Many environmental risk factors are associated with HCC, including chronic hepatitis B (HBV) or hepatitis C viral infections, exposure to dietary aflatoxin B1, cigarette smoking, alcohol consumption, diabetes mellitus, and conditions such as cirrhosis [@B07]-[@B10]. Furthermore, it is generally accepted that genetic factors play important roles in the pathogenesis of HCC [@B11],[@B12]. The exact mechanism of hepatocarcinogenesis is still incompletely understood.

The human multidrug resistance 1 (*MDR1*) gene encodes a 170-kDa transmembrane protein, P-glycoprotein (Pgp), which is a membrane protein acting as an ATP-dependent exporter of xenobiotics from cells [@B13]. This MDR1 protein anchors to the cell membrane and acts as an efflux transporter conferring resistance to a variety of natural cytotoxic drugs and potentially toxic xenobiotics [@B14]-[@B17]. It has been reported that *MDR1* is an important candidate gene influencing the risk for HCC. Previous studies have mainly focused on the expression of *MDR1* (often referred to as Pgp) in HCC cell lines and HCC specimens, with heterogeneous and divergent results. It has been suggested that single nucleotide polymorphisms (SNPs) in the *MDR1* gene may have an impact on the expression and function of Pgp, therefore influencing susceptibility to various diseases, including liver cancer [@B18]-[@B25]. *MDR1* is polymorphic, and at least 50 SNPs have been reported [@B17],[@B23]-[@B30]. Previous studies have reported the association of *MDR1* gene polymorphisms with HCC risk factors [@B25],[@B31],[@B32]. However, the association of the *MDR1* gene c.335T\>C and c.3073A\>C SNPs with HCC has not been investigated. Thus, in the present study, we indentified these genetic polymorphisms in the *MDR1* gene and evaluated their association with the risk of liver cancer in the Chinese population.

Subjects and Methods
====================

Subjects
--------

In this case-control study, 353 patients with HCC were enrolled from January 2008 to December 2011. HCC patients were diagnosed by doctors according to the standards established by the Chinese Society of Liver Cancer (CSLC). The control group consisted of 335 healthy subjects randomly selected from participants in health screening programs to exclude those with a medical history of surgery, cancer and other disease. All subjects were unrelated individuals of the Han nationality. Information was obtained regarding demographic data as well as related risk factors such as gender, age, smoking, drinking, hypertension, diabetes mellitus, serum a-FP levels, family history of HCC, and HBV serological markers \[hepatitis-B surface antigen (HBs Ag), hepatitis-B surface antibody (HBs Ab), hepatitis-Be antigen (HBe Ag), antibody to hepatitis-Be antigen (anti-HBe Ab), and antibody to hepatitis-B core antigen (anti-HBc)\] ([Table 1](#t01){ref-type="table"}). The current study was approved by the local Institutional Ethics Committee, and all subjects gave written informed consent to participate.

Table 1Characteristics of the hepatocellular carcinoma (HCC) patients and controls.[^1]

Primer design and polymerase chain reaction (PCR) amplification
---------------------------------------------------------------

Genomic DNA was extracted from peripheral venous blood using the standard phenol/chloroform extraction method. According to the DNA sequences (GenBank ID: NG_011513.1) and mRNA sequences (GenBank ID: NM_000927.4) of the *MDR1* gene, specific PCR primers were designed using the Primer Premier 5.0 software (PREMIER Biosoft International, Canada). Primers, annealing temperature, region, fragment sizes, and selected restriction enzymes (MBI Fermentas, Germany) are shown in [Table 2](#t02){ref-type="table"}. PCR was carried out in a total volume of 20 µL containing 50 ng template DNA, 1X buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 0.25 µM primers, 2.0 mM MgCl~2~, 0.25 mM dNTPs, and 0.5 U Taq DNA polymerase (Promega, USA). The PCR protocol was 94°C for 5 min, followed by 35 cycles at 94°C for 30 s, annealing at the corresponding temperature (shown in [Table 2](#t02){ref-type="table"}) for 30 s and 72°C for 30 s, and a final extension at 72°C for 8 min. The PCR products were separated on 1.5% agarose gel and photographed under UV light.

Table 2PCR, PCR-RFLP and CRS-PCR analysis used to genotype SNPs in the *MDR1* gene.[^2]

*MDR1* genotyping
-----------------

c.335T\>C was investigated using the created restriction site-PCR (CRS-PCR) method with one of the primers containing a nucleotide mismatch, which enables the use of restriction enzymes for discriminating sequence variations [@B33]-[@B35]. c.3073A\>C was detected by the PCR-restriction fragment length polymorphism (PCR-RFLP) method. Following the supplier\'s manual, 5-µL aliquots of PCR-amplified products were digested with 2 U restriction enzyme at 37°C for 10 h. The digested products were separated by 2.5% agarose gel electrophoresis and observed directly under UV light in order to determine the genotype of MDR1 polymorphisms. To confirm the genotype results obtained by CRS-PCR and PCR-RFLP, about 20% of PCR-amplified products were randomly selected for DNA sequencing (TaKaRa Biotechnology Co., Ltd., China).

Statistical analyses
--------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences software (SPSS, Windows version release 15.0; SPSS Inc., USA). The chi-square (χ^2^) test was applied to evaluate Hardy--Weinberg equilibrium in all individuals, as well as allele and genotype frequencies, and the general characteristics of the groups. Associations between *MDR1* gene polymorphisms and HCC risk were estimated using odds ratios (OR) and 95% confidence intervals (95%CI) for the comparison of homozygotes (c.335T\>C: CC *vs* TT, and c.3073A\>C: CC *vs* AA), and heterozygotes (c.335T\>C: TC *vs* TT, and c.3073A\>C: AC *vs* AA), dominant model (c.335T\>C: CC+TC *vs* TT, and c.3073A\>C: CC+AC *vs* AA), recessive model (c.335T\>C: CC *vs* TC+TT, and c.3073A\>C: CC *vs* AC+AA) and allele contrast (c.335T\>C: C *vs* T, and c.3073A\>C: C *vs* A). For all statistical tests, P \< 0.05 was defined as statistically significant.

Results
=======

General characteristics of the subjects
---------------------------------------

A total of 688 subjects were recruited for this study, including 353 HCC patients and 335 controls. No significant differences between the patients and controls in terms of gender and age distribution suggested that matching of subjects based on these variables was adequate. Similarly, there were no significant differences in smoking status or drinking consumption, hypertension or diabetes mellitus between the patients and controls. The general characteristics of the populations are summarized in [Table 1](#t01){ref-type="table"}.

Detection and genotyping of *MDR1* SNPs
---------------------------------------

In the present study, two allelic variants (c.335T\>C and c.3073A\>C) were investigated by the CRS-PCR and PCR-RFLP methods, respectively. Sequence analysis suggested that the c.335T\>C polymorphism was caused by T to C mutations in the 5′-UTR of the human *MDR1* gene. As was the case for the c.3073A\>C variant, sequence analysis showed that this allelic variant was caused by A to C mutations in exon 22 of the human *MDR1* gene. Furthermore, this polymorphism caused a leucine (Leu) to phenylalanine (Phe) amino acid replacement (p.Leu860Phe, Reference sequence GenBank IDs: NG_011513.1, NM_000927.4 and NP_000918.2). The PCR product of c.335T\>C was digested with the *Nla*III enzyme and divided into three genotypes: TT (208 bp), TC (208, 185, and 23 bp) and CC (185 and 23 bp; [Table 2](#t02){ref-type="table"}). The PCR product of c.3073A\>C was digested with the *Mae*III enzyme and divided into three genotypes: AA (163 and 86 bp), AC (249, 163, and 86 bp) and CC (249 bp; [Table 2](#t02){ref-type="table"}).

Allelic and genotypic frequencies
---------------------------------

The chi-square (χ^2^) test for the c.335T\>C and c.3073A\>C variants in the studied subjects suggested that the polymorphic sites were in Hardy-Weinberg equilibrium (P \> 0.05; [Table 3](#t03){ref-type="table"}). The allelic and genotypic frequencies of the c.335T\>C and c.3073A\>C polymorphisms are presented in [Table 3](#t03){ref-type="table"}. Allele T and allele A were the predominant alleles in the studied subjects in c.335T\>C and c.3073A\>C, respectively ([Table 3](#t03){ref-type="table"}). Regarding the c.335T\>C variant, the allelic frequencies of the patients (T = 61.19%; C = 38.81%) were significantly different from those of controls (T = 70.45%; C = 29.55%; χ^2^ = 13.0743; P = 0.0003). Furthermore, the genotypic frequencies of the patients were not similar to those of the controls, with the differences being statistically significant (χ^2^ = 11.8639; P = 0.0027; [Table 3](#t03){ref-type="table"}). Similarly, for the c.3073A\>C variant, the allelic frequencies of the patients (A = 55.24%; C = 44.76%) were significantly different from those of the controls (A = 67.01%; C = 32.99%; χ^2^ = 20.0272; P \< 0.0001; [Table 3](#t03){ref-type="table"}). The genotypic frequencies of the patients were not similar to those of the controls, with the differences being statistically significant (χ^2^ = 18.4030; P = 0.0001; [Table 3](#t03){ref-type="table"}).

Table 3Genotypic and allelic frequencies of c.335T\>C and c.3073A\>C polymorphisms in the studied subjects.[^3]

*MDR1* polymorphisms and risk of HCC
------------------------------------

Analysis of the association of genotypes/alleles from the c.335T\>C and c.3073A\>C SNPs with the risk of HCC suggested that there was a significantly increased risk of HCC ([Table 4](#t04){ref-type="table"}). Regarding the c.335T\>C SNPs, a significantly increased risk of liver cancer was found in the homozygote comparison (CC *vs* TT: OR = 2.161, 95%CI = 1.350-3.459, χ^2^ = 10.55; P = 0.0011), heterozygote comparison (TC *vs* TT: OR = 1.430, 95%CI = 1.034-1.977, χ^2^ = 4.68; P = 0.0310), dominant model (CC+TC *vs* TT: OR = 1.587, 95%CI = 1.173-2.146, χ^2^ = 9.01; P = 0.0027), recessive model (CC *vs* TC+TT: OR = 1.826, 95%CI = 1.171-2.849, χ^2^ = 7.19; P = 0.0073), and allele contrast (C *vs* T: OR = 1.512, 95%CI = 1.208-1.893, χ^2^ = 13.07; P = 0.0003; [Table 4](#t04){ref-type="table"}). Similarly, there were significant differences in the c.3073A\>C SNPs for homozygote comparison (CC *vs* AA: OR = 2.575, 95%CI = 1.646-4.028, χ^2^ = 17.64; P \< 0.0001), heterozygote comparison (AC *vs* AA: OR = 1.519, 95%CI = 1.090-2.116, χ^2^ = 6.13; P = 0.0130), dominant model (CC+AC *vs* AA: OR = 1.759, 95%CI = 1.292-2.396, χ^2^ = 12.94; P = 0.0003), recessive model (CC *vs* AC+AA: OR = 2.067, 95%CI = 1.370-3.120, χ^2^ = 12.28; P = 0.0005), and allele contrast (C *vs* A: OR = 1.646, 95%CI = 1.322-2.049, χ^2^ = 20.03; P \< 0.0001; [Table 4](#t04){ref-type="table"}).

Table 4Association between hepatocellular carcinoma risk and *MDR1* SNPs.[^4]

Discussion
==========

HCC is a common primary malignant tumor of the liver resulting from complex interactions between environmental and genetic factors. Genotypic variation has a key function in human phenotypic variability for cancer susceptibility. The present study provided novel information on the effects of two novel allelic variants (c.335T\>C and c.3073A\>C) of *MDR1* on susceptibility to HCC. We observed a significant difference in allelic and genotypic frequencies between HCC patients and healthy controls ([Table 3](#t03){ref-type="table"}). Regarding the c.335T\>C variants, the CC genotype was strongly associated with an increased risk of developing HCC compared to TT and TC/TT genotypes. The risk of HCC was significantly higher for the CC genotype in the c.3073A\>C polymorphism compared to the AA genotype and AC/AA carriers. Thus, the C allele of both c.335T\>C and c.3073A\>C variants may contribute to the risk of HCC (C *vs* T of c.335T\>C: OR = 1.512, 95%CI = 1.208-1.893; P = 0.0003 and C *vs* A of c.3073A\>C: OR = 1.646, 95%CI = 1.322-2.049; P \< 0.0001). The results of the present study suggest that the c.335T\>C and c.3073A\>C polymorphisms of the *MDR1* gene are associated with the risk of occurrence of HCC in the Chinese Han population. Several previous studies have confirmed the relationship between *MDR1* polymorphisms and risk factors for HCC [@B25],[@B31],[@B32]. Wu et al. [@B25] analyzed the association between three polymorphisms (C1236T, G2677A/T, C3435T) of the *MDR1* gene and the risk of recurrence after liver transplantation. The association between recurrence-free condition and being a 2677A carrier was significant (P = 0.019), but no significant association was observed with other polymorphisms [@B25]. Wu et al. suggested that polymorphism of the *MDR1* gene may be a valuable molecular marker for HCC recurrence after liver transplantation. Chen et al. [@B31] investigated the association between G2677T/A polymorphisms of the *MDR1* gene and the risk of HCC [@B31] and suggested that 2677A may be an allele protecting against HCC, while 2677T may be a risk gene for HCC [@B31]. Chen et al. [@B32] detected a correlation of two polymorphisms (C1236T and C3435T) of the *MDR1* gene with the prognosis of HCC. The correlation between prognosis of HCC and the C3435T polymorphism was significant (P = 0.037), but no significant correlation was observed for the C1236T polymorphism (P = 0.762) [@B32].

These findings suggested that the C3435T could be a positive candidate molecular marker for the prognosis of HCC [@B32]. To the best of our knowledge, this is the first report regarding the association of the *MDR1* gene c.335T\>C and c.3073A\>C SNPs with the risk of HCC. The findings could provide new evidence for further analysis of the importance of the *MDR1* polymorphism for the risk of HCC. Larger prospective studies will be needed to confirm these results in different populations.

[^1]: Data are reported as number with percent in parentheses except for mean ± SD age. HBV = hepatitis B virus; HBs Ag = hepatitis B surface antigen; a-FP = alpha-fetoprotein. Patients and controls were compared by the chi-square (χ^2^) test. There were no statistically significant differences.

[^2]: PCR = polymerase chain reaction; PCR-RFLP = PCR-restriction fragment length polymorphism; CRS-PCR = created restriction site PCR; SNPs = single nucleotide polymorphisms. Underlined nucleotide indicates nucleotide mismatch enabling the use of the selected restriction enzymes for discriminating sequence variations.

[^3]: The chi-square (χ^2^) test was used to evaluate Hardy-Weinberg equilibrium in allele and genotype frequencies in patients and controls.

[^4]: SNPs = single nucleotide polymorphisms. The association of *MDR1* gene polymorphisms with hepatocellular carcinoma risk was estimated using odds ratios (OR) and 95% confidence intervals (95%CI) for the comparison of homozygotes, heterozygotes, dominant model, recessive model, and allele contrast by the chi-square (χ^2^) test.
